Skip to main content

Table 2 Subjects With a Vaccine Response and rSBA GMTs After the MenACWY-TT Booster Dose

From: A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

 Vaccine Response,a % (CI)GMT, % (CI)
1 Month After
MenACWY-TT Booster
Before
MenACWY-TT Booster
1 Month After
MenACWY-TT Booster
Serogroup A
 Primary MenACWY-TT (n = 155)87.7 (81.5, 92.5)153.8 (108.1, 218.6)4059.5 (3383.8, 4870.2)
 Primary MenACWY-PS (n = 52)88.5 (76.6, 95.6)75.1 (41.4, 136.4)3584.8 (2750.7, 4672.0)
Serogroup C
 Primary MenACWY-TT (n = 154)90.9 (85.2, 94.9)192.8 (140.6, 264.4)13,823.5 (10,839.7, 17,628.7)
 Primary MenACWY-PS (n = 52)75.0 (61.1, 86.0)212.4 (109.6, 411.8)3444.3 (1998.5, 5936.0)
Serogroup W
 Primary MenACWY-TT (n = 154)94.2 (89.2, 97.3)166.2 (107.1, 257.9)24,431.0 (17,351.4, 31,640.7)
 Primary MenACWY-PS (n = 52)96.2 (86.8, 99.5)10.9 (6.1, 19.3)5792.6 (3585.9, 9357.4)
Serogroup Y
 Primary MenACWY-TT (n = 154)83.8 (77.0, 89.2)363.7 (254.6, 519.4)8958.4 (7601.6, 10,557.5)
 Primary MenACWY-PS (n = 52)92.3 (81.5, 97.9)56.0 (28.8, 109.1)5137.8 (3528.2, 7481.6)
  1. GMT geometric mean titer, MenACWY meningococcal A, C, W, Y, PS polysaccharide, rSBA serum bactericidal antibody assay using baby rabbit complement, TT tetanus toxoid
  2. Data are for subjects in the booster according-to-protocol cohort
  3. aVaccine response was defined as an rSBA titer ≥1:32 in subjects who were seronegative (rSBA titer <1:8) before booster vaccination and as a ≥4-fold increase from prevaccination titers in subjects who were seropositive before vaccination